Characterization of Virologic Rebound Following Nirmatrelvir-Ritonavir Treatment for Coronavirus Disease 2019 (COVID-19)

被引：73
|
作者：
Boucau, Julie [1 ]
Uddin, Rockib [2 ]
Marino, Caitlin [1 ]
Regan, James [3 ]
Flynn, James P. [3 ]
Choudhary, Manish C. [3 ,4 ]
Chen, Geoffrey [2 ]
Stuckwisch, Ashley M. [2 ]
Mathews, Josh [2 ]
Liew, May Y. [2 ]
Singh, Arshdeep [2 ]
Reynolds, Zahra [2 ]
Iyer, Surabhi L. [2 ]
Chamberlin, Grace C. [2 ]
Vyas, Tammy D. [2 ]
Vyas, Jatin M. [2 ,4 ]
Turbett, Sarah E. [2 ]
Li, Jonathan Z. [3 ,4 ]
Lemieux, Jacob E. [2 ,4 ,5 ]
Barczak, Amy K. [1 ,2 ,4 ]
Siedner, Mark J. [2 ,4 ]
机构：
[1] Massachusetts Inst Technol MIT & Harvard, Massachusetts Gen Hosp MGH, Ragon Inst, Cambridge, MA USA
[2] Massachusetts Gen Hosp, Boston, MA 02215 USA
[3] Brigham & Womens Hosp, Boston, MA 02215 USA
[4] Harvard Med Sch, Boston, MA 02215 USA
[5] Broad Inst, Cambridge, MA 02138 USA
来源：
CLINICAL INFECTIOUS DISEASES | 2023年 / 76卷 / 03期
关键词：
COVID-19; therapeutics; anti-virals; nirmatrelvir-ritonavir; virology;
D O I：
10.1093/cid/ciac512
中图分类号：
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号：
100102 ;
摘要：
We enrolled 7 individuals with recurrent symptoms or antigen test conversion following nirmatrelvir-ritonavir treatment. High viral loads (median 6.1 log(10) copies/mL) were detected after rebound for a median of 17 days after initial diagnosis. Three had culturable virus for up to 16 days after initial diagnosis. No known resistance-associated mutations were identified.
引用
收藏
页码：E526 / E529
页数：4
相关论文
共 50 条
  • [41] Rebound of SARS-CoV-2 Infection after Nirmatrelvir-Ritonavir Treatment
    Charness, Michael E.
    Gupta, Kalpana
    Stack, Gary
    Strymish, Judith
    Adams, Eleanor
    Lindy, David C.
    Mohri, Hiroshi
    Ho, David D.
    NEW ENGLAND JOURNAL OF MEDICINE, 2022, 387 (11): : 1045 - 1047
  • [42] A Systematic Review of Nirmatrelvir/Ritonavir and Molnupiravir for the Treatment of Coronavirus Disease 2019
    Haslam, Alyson
    Prasad, Vinay
    OPEN FORUM INFECTIOUS DISEASES, 2024, 11 (09):
  • [43] Comparative effectiveness of combination therapy with nirmatrelvir-ritonavir and remdesivir versus monotherapy with remdesivir or nirmatrelvir-ritonavir in patients hospitalised with COVID-19: a target trial emulation study
    Choi, Ming Hong
    Wan, Eric Yuk Fai
    Wong, Ian Chi Kei
    Chan, Esther Wai Yin
    Chu, Wing Ming
    Tam, Anthony Raymond
    Yuen, Kwok Yung
    Hung, Ivan Fan Ngai
    LANCET INFECTIOUS DISEASES, 2024, 24 (11):
  • [44] Effectiveness of nirmatrelvir-ritonavir on severe outcomes of COVID-19: A meta-regression analysis
    Chen, I-Wen
    Yu, Ting-Sian
    Lin, Chien-Hung
    Hung, Kuo-Chuan
    JOURNAL OF MEDICAL VIROLOGY, 2024, 96 (06)
  • [45] Effectiveness of nirmatrelvir-ritonavir versus azvudine for adult inpatients with severe or critical COVID-19
    Zhang, Huan
    Tan, Xiaojiao
    Chen, Junjun
    Zhang, Zheng
    Wang, Chenxi
    Shi, Haiqing
    Li, Yao
    Li, Jianbo
    Kang, Yan
    Jin, Xiaodong
    Liao, Xuelian
    BMJ OPEN RESPIRATORY RESEARCH, 2024, 11 (01)
  • [46] COVID-19 "Rebound" associated with nirmatrelvir/ritonavir pre-hospital therapy
    Coulson, J. M.
    Adams, A.
    Gray, L. A.
    Evans, A.
    JOURNAL OF INFECTION, 2022, 85 (04) : 476 - 477
  • [47] Nirmatrelvir treatment duration and frequency of COVID-19 rebound
    Sudeep, Nathan
    Kojima, Noah
    Klausner, Jeffrey D.
    ANTIVIRAL THERAPY, 2025, 30 (01)
  • [48] Symptoms, Viral Loads, and Rebound Among Coronavirus Disease 2019 (COVID-19) Outpatients Treated With Nirmatrelvir/Ritonavir Compared With Propensity Score-Matched Untreated Individuals
    Smith-Jeffcoat, Sarah E.
    Biddle, Jessica E.
    Talbot, H. Keipp
    Morrissey, Kerry Grace
    Stockwell, Melissa S.
    Maldonado, Yvonne
    McLean, Huong Q.
    Ellingson, Katherine D.
    Bowman, Natalie M.
    Asturias, Edwin
    Mellis, Alexandra M.
    Johnson, Sheroi
    Kirking, Hannah L.
    Rolfes, Melissa A. R.
    Olivo, Vanessa
    Merrill, Lori
    Battan-Wraith, Steph
    Sano, Ellen
    McLaren, Son H.
    Vargas, Celibell Y.
    Goodman, Sara
    Sarnquist, Clea C.
    Govindaranjan, Prasanthi
    Petrie, Joshua G.
    Belongia, Edward A.
    Ledezma, Karla
    Pryor, Kathleen
    Lutrick, Karen
    Bullock, Ayla
    Yang, Amy
    Haehnel, Quenla
    Rao, Suchitra
    Zhu, Yuwei
    Schmitz, Jonathan
    Hart, Kimberly
    Grijalva, Carlos G.
    Salvatore, Phillip P.
    CLINICAL INFECTIOUS DISEASES, 2023, : 1175 - 1184
  • [49] SARS-CoV-2 Virologic Rebound With Nirmatrelvir-Ritonavir Therapy (vol 176, pg 1577, 2023)
    Edelstein, G. E.
    Boucau, J.
    Uddin, R.
    ANNALS OF INTERNAL MEDICINE, 2024, 177 (04) : 547 - 547
  • [50] Clinical outcomes of nirmatrelvir-ritonavir use in pregnant women during the Omicron wave of the coronavirus disease 2019 pandemic
    Lin, Chih-Wei
    Liang, Yu-Ling
    Chuang, Ming-Ta
    Tseng, Chun-Han
    Tsai, Pei-Yin
    Su, Mei-Tsz
    JOURNAL OF INFECTION AND PUBLIC HEALTH, 2023, 16 (12) : 1942 - 1946
12345